Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.35 USD | -1.40% | +0.32% | +92.72% |
Jun. 03 | Neurogene's Gene Therapy For Rett Syndrome Picked For FDA Pilot Program | MT |
Jun. 03 | Neurogene Inc. Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for Start Pilot Program | CI |
Valuation
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Capitalization 1 | 248.5 | 484.8 | - | - |
Enterprise Value (EV) 1 | 51.47 | 157.7 | -16.29 | 484.8 |
P/E ratio | -2.49 x | -9.03 x | -9.45 x | -7.87 x |
Yield | - | - | - | - |
Capitalization / Revenue | - | - | - | - |
EV / Revenue | - | - | - | - |
EV / EBITDA | - | - | - | - |
EV / FCF | -0.99 x | -2.29 x | 0.21 x | -5.84 x |
FCF Yield | -101% | -43.8% | 467% | -17.1% |
Price to Book | - | - | - | - |
Nbr of stocks (in thousands) | 12,824 | 12,980 | - | - |
Reference price 2 | 19.38 | 37.35 | 37.35 | 37.35 |
Announcement Date | 3/18/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA | - | - | - | - | - |
EBIT 1 | - | -55.58 | -80.76 | -86.68 | -106.9 |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -36.32 | -70.27 | -78.98 | - |
Net income 1 | -55.19 | -36.32 | -72.01 | -83.47 | -98.55 |
Net margin | - | - | - | - | - |
EPS 2 | -10.58 | -7.798 | -4.136 | -3.952 | -4.743 |
Free Cash Flow 1 | - | -51.74 | -69 | -76 | -83 |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 11/8/23 | 3/18/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | -14.73 | -18.78 | -19.85 | -20.65 | -21.52 | -19.95 | -20.25 |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | 2.383 | -16.92 | -17.3 | -17.76 | -18.28 | -18.74 | -19.21 |
Net income 1 | 2.383 | -16.92 | -17.5 | -18.42 | -19.19 | -18.74 | -19.21 |
Net margin | - | - | - | - | - | - | - |
EPS 2 | - | -1.000 | -1.025 | -1.072 | -1.007 | -1.045 | -1.040 |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 3/18/24 | 5/10/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - |
Net Cash position 1 | - | 197 | 327 | 501 | - |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow 1 | - | -51.7 | -69 | -76 | -83 |
ROE (net income / shareholders' equity) | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets 1 | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex 1 | - | 0.32 | 1.5 | 1.1 | - |
Capex / Sales | - | - | - | - | - |
Announcement Date | 11/8/23 | 3/18/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+92.72% | 485M | |
+49.41% | 56.95B | |
+40.49% | 40.26B | |
-6.72% | 39.32B | |
-5.96% | 28.37B | |
+12.99% | 26.45B | |
-19.82% | 19.41B | |
+32.35% | 12.54B | |
-0.08% | 12.15B | |
+25.18% | 12.21B |
- Stock Market
- Equities
- NGNE Stock
- Financials Neurogene Inc.